Boutique asset manager specializing in tax-advantaged and alternative credit strategies for institutional and high-net-worth clients, with an emphasis on cash-flow-oriented private credit and structured financing. Sugar Maple Asset Management, LLC positions itself as a nimble allocator across direct lending, specialty finance and collateralized credit, leveraging bespoke underwriting, portfolio construction and risk-management processes to target income generation and capital preservation. Relevant to allocators seeking diversified yield exposure in illiquid credit markets.
Boutique asset manager specializing in tax-advantaged and alternative credit strategies for institutional and high-net-worth clients, with an emphasis on cash-flow-oriented private credit and structured financing. Sugar Maple Asset Management, LLC positions itself as a nimble allocator across direct lending, specialty finance and collateralized credit, leveraging bespoke underwriting, portfolio construction and risk-management processes to target income generation and capital preservation. Relevant to allocators seeking diversified yield exposure in illiquid credit markets.
Focuses on tax-advantaged and alternative credit mandates, emphasizing cash-flow-driven private credit, structured financings and specialty finance. Pursues nimble, income-oriented capital deployment across direct lending and collateralized credit with a bias toward bespoke underwriting, conservative leverage and scenario-based stress testing. Portfolio construction blends yield generation with capital preservation via diversified exposures, tranche selection and active liquidity management. Targets institutional and high-net-worth allocators seeking durable, illiquidity premia; decision-making prioritizes downside protection, sponsor alignment and repeatable risk-adjusted income over short-term market timing.
Focuses on tax-advantaged and alternative credit mandates, emphasizing cash-flow-driven private credit, structured financings and specialty finance. Pursues nimble, income-oriented capital deployment across direct lending and collateralized credit with a bias toward bespoke underwriting, conservative leverage and scenario-based stress testing. Portfolio construction blends yield generation with capital preservation via diversified exposures, tranche selection and active liquidity management. Targets institutional and high-net-worth allocators seeking durable, illiquidity premia; decision-making prioritizes downside protection, sponsor alignment and repeatable risk-adjusted income over short-term market timing.
| Trades 1017 | Longs Won 565/1017 55% | Profit Factor 6.44 |
| Profitability | Shorts Won 0/0 0% | Standard Deviation $215,785.51 |
| Average Win $66,210.25 | Best Trade (Sep 01) $4.29M | Sharpe Ratio -21.86 |
| Average Loss -$12,855.2 | Worst Trade (Sep 01) -$955,800.39 | Z-Score -1.44 (85.51%) |
| Commissions $0 | Avg. Trade Length 8m 1w | Expectancy $31,070.05 |
| Loss Size | 100% | 90% | 80% | 70% | 60% | 50% | 40% | 30% | 20% | 10% |
| Probability of Loss | <0.01% | <0.01% | <0.01% | <0.01% | <0.01% | <0.01% | <0.01% | <0.01% | <0.01% | <0.01% |
| Consecutive Losing Trades | 12,500 | 11,250 | 10,000 | 8,750 | 7,500 | 6,250 | 5,000 | 3,750 | 2,500 | 1,250 |
| Symbol | Quantity | Cost | Value | Comm. | Profit ($) | Gain (%) | Change |
|---|---|---|---|---|---|---|---|
AAPL Apple Inc. | 2,093 | $493,156.29 | $646,548.63 | - | $153,392.34 | 31.1% | -7.354% |
ABBV AbbVie Inc. | 56,269 | $10.25M | $14.12M | - | $3.87M | 37.76% | -2.513% |
ABT Abbott Laboratories | 67,187 | $7.63M | $7.1M | - | -$530,937.72 | -6.96% | +0.085% |
ADMA Adma Biologics Inc. | 15,500 | $129,735 | $131,130 | - | $1,395 | 1.08% | -2.422% |
AGG iShares Core U.S. Aggregate Bond ETF | 15,540 | $1.54M | $1.51M | - | -$29,525.96 | -1.91% | -0.256% |
ALAB ASTERA LABS INC COMMON STOCK (Ticker: 1ALAB) | 500 | $241,510 | $155,615 | - | -$85,895 | -35.57% | +3.851% |
AMZN Amazon.com Inc | 3,249 | $622,348.06 | $882,363.39 | - | $260,015.33 | 41.78% | +15.321% |
AQST Aquestive Therapeutics Inc. | 83,060 | $450,682.5 | $306,906.7 | - | -$143,775.8 | -31.9% | -0.672% |
ASML ASML Holding N.V. New York Registry Shares | 175 | $231,145 | $285,075 | - | $53,930 | 23.33% | -1.359% |
| AUGP AUGP | 13,500 | $411,090 | $411,090 | - | - | - | 0.0 |
BALT Inn Defined Wealth Shield Mutual Fund | 13,500 | $443,070 | $464,940 | - | $21,870 | 4.94% | +0.175% |
BKDV BNY Mellon Dynamic Value ETF | 93,788 | $2.82M | $3.19M | - | $369,876.13 | 13.12% | +0.92% |
CGSM Capital Group Short Duration Municipal Income ETF | 15,291 | $402,261.44 | $400,624.2 | - | -$1,637.24 | -0.41% | -0.304% |
CLOI VanEck CLO ETF | 77,902 | $4.12M | $4.13M | - | $12,663.82 | 0.31% | -0.057% |
CNEQ Alger Concentrated Equity ETF | 16,869 | $640,684.62 | $648,275.67 | - | $7,591.05 | 1.18% | +1.185% |
CPSM Calamos S&P 500 Structured Alt Protection ETF – May | 39,000 | $1M | $1.14M | - | $140,925 | 14.04% | +0.14% |
DOG ProShares Short Dow30 | 63,000 | $1.48M | $1.36M | - | -$115,920 | -7.83% | -0.506% |
EMXC iShares MSCI Emerging Markets ex China ETF | 9,593 | $816,002.43 | $883,707.16 | - | $67,704.73 | 8.3% | +1.031% |
FBCG Fidelity Blue Chip Growth Fund | 18,618 | $1.01M | $1.11M | - | $100,146.09 | 9.89% | +1.151% |
FBND Fidelity Total Bond ETF | 55,170 | $2.54M | $2.47M | - | -$71,072.97 | -2.8% | -0.268% |